IN2014DN10801A - - Google Patents
Info
- Publication number
- IN2014DN10801A IN2014DN10801A IN10801DEN2014A IN2014DN10801A IN 2014DN10801 A IN2014DN10801 A IN 2014DN10801A IN 10801DEN2014 A IN10801DEN2014 A IN 10801DEN2014A IN 2014DN10801 A IN2014DN10801 A IN 2014DN10801A
- Authority
- IN
- India
- Prior art keywords
- inhibitor
- imatinib
- gist
- therapy
- fgfr
- Prior art date
Links
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 abstract 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 abstract 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 2
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 2
- 229960002411 imatinib Drugs 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 229940124204 C-kit inhibitor Drugs 0.000 abstract 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002250 progressing effect Effects 0.000 abstract 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 abstract 1
- 229960001796 sunitinib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to a method of treating gastrointestinal stromal tumors (GIST) especially GIST which is progressing after imatinib therapy or after imatinib and sunitinib therapy using a combination comprising (a) a c kit inhibitor and (b) a dual KIT inhibitor and FGFR inhibitor or FGFR inhibitor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670168P | 2012-07-11 | 2012-07-11 | |
PCT/US2012/061535 WO2013063003A1 (en) | 2011-10-28 | 2012-10-24 | Method of treating gastrointestinal stromal tumors |
PCT/US2013/036273 WO2014011284A1 (en) | 2012-07-11 | 2013-04-12 | Method of treating gastrointestinal stromal tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN10801A true IN2014DN10801A (en) | 2015-09-04 |
Family
ID=49916465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN10801DEN2014 IN2014DN10801A (en) | 2012-07-11 | 2013-04-12 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150202203A1 (en) |
EP (1) | EP2872142A1 (en) |
JP (1) | JP2015522070A (en) |
KR (1) | KR20150036014A (en) |
CN (1) | CN104427986A (en) |
AU (1) | AU2013289175A1 (en) |
BR (1) | BR112015000349A2 (en) |
CA (1) | CA2878251A1 (en) |
IN (1) | IN2014DN10801A (en) |
MX (1) | MX2015000457A (en) |
RU (1) | RU2015104537A (en) |
WO (1) | WO2014011284A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
CN107652289B (en) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | Substituted tricyclic compounds as FGFR inhibitors |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
JP6449244B2 (en) | 2013-04-19 | 2019-01-09 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
WO2016134320A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
HUE057043T2 (en) * | 2016-01-11 | 2022-04-28 | Merck Patent Gmbh | Quinolin-2-one derivatives |
CA3061179A1 (en) | 2017-05-05 | 2018-11-08 | Csp Technologies, Inc. | Container having child-resistant senior-friendly features and method of using and making same |
AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
DK3788047T3 (en) | 2018-05-04 | 2024-09-16 | Incyte Corp | Solid forms of an FGFR inhibitor and methods of making the same |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US10835531B1 (en) * | 2019-06-18 | 2020-11-17 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US20220323412A1 (en) * | 2019-09-06 | 2022-10-13 | Chi-Chih Kang | Extracellular vesicle-fenretinide compositions, extracellular vesicle-c-kit inhibitor compositions, methods of making and uses thereof |
MX2022004513A (en) | 2019-10-14 | 2022-07-19 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors. |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JP2023505258A (en) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Tricyclic heterocycles as FGFR inhibitors |
BR112022010664A2 (en) | 2019-12-04 | 2022-08-16 | Incyte Corp | DERIVATIVES OF A FGFR INHIBITOR |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US20230097907A1 (en) | 2020-01-27 | 2023-03-30 | Mantra Bio, Inc. | Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof |
EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
CO4940418A1 (en) | 1997-07-18 | 2000-07-24 | Novartis Ag | MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE |
US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
PT1650203E (en) | 2000-09-11 | 2008-05-13 | Novartis Vaccines & Diagnostic | Process of preparation of benzimidazol-2-yl quinolinone derivatives |
GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
ITTV20030095A1 (en) | 2003-07-14 | 2005-01-15 | Asolo Spa | FOOTWEAR WITH COMPOSITE INSOLE. |
KR101167573B1 (en) | 2003-11-07 | 2012-07-30 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
ES2440799T3 (en) | 2005-05-13 | 2014-01-30 | Novartis Ag | Methods to treat drug resistant cancer |
CA2609353C (en) | 2005-05-23 | 2015-04-28 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
GT200600315A (en) | 2005-07-20 | 2007-03-19 | CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA | |
GT200600316A (en) | 2005-07-20 | 2007-04-02 | SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA. | |
PT1957074E (en) | 2005-11-29 | 2014-06-25 | Novartis Ag | Formulations of quinolinones |
EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
PE20091628A1 (en) | 2008-03-19 | 2009-11-19 | Novartis Ag | CRYSTALLINE FORMS AND TWO SOLVATED FORMS OF LACTIC ACID SALTS OF 4-AMINO-5-FLUORO-3- [5- (4-METHYLPIPERAZIN-1-IL) -1H-BENZIMIDAZOL-2-IL] QUINOLIN-2 (1H) - ONA |
JP5351254B2 (en) | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | Quinoxaline- and quinoline-carboxamide derivatives |
UY33472A (en) | 2010-06-30 | 2012-01-31 | Novartis Ag | ? PHARMACEUTICAL COMPOSITIONS THAT INCLUDE 4-AMINO-5-FLUORO-3- LACTATE MONOHIDRATE [6- (4-METHYL-PIPERAZIN-1-IL) -1HBENCIMIDAZOL-2-IL] -1H-QUINOLIN-2-ONA ?. |
AU2012328979B2 (en) * | 2011-10-28 | 2016-04-21 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
-
2013
- 2013-04-12 JP JP2015521607A patent/JP2015522070A/en active Pending
- 2013-04-12 US US14/413,045 patent/US20150202203A1/en not_active Abandoned
- 2013-04-12 KR KR20157000335A patent/KR20150036014A/en not_active Application Discontinuation
- 2013-04-12 EP EP13718720.9A patent/EP2872142A1/en not_active Withdrawn
- 2013-04-12 CA CA 2878251 patent/CA2878251A1/en not_active Abandoned
- 2013-04-12 RU RU2015104537A patent/RU2015104537A/en unknown
- 2013-04-12 WO PCT/US2013/036273 patent/WO2014011284A1/en active Application Filing
- 2013-04-12 CN CN201380037065.7A patent/CN104427986A/en active Pending
- 2013-04-12 IN IN10801DEN2014 patent/IN2014DN10801A/en unknown
- 2013-04-12 MX MX2015000457A patent/MX2015000457A/en unknown
- 2013-04-12 AU AU2013289175A patent/AU2013289175A1/en not_active Abandoned
- 2013-04-12 BR BR112015000349A patent/BR112015000349A2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2013289175A1 (en) | 2015-01-22 |
JP2015522070A (en) | 2015-08-03 |
EP2872142A1 (en) | 2015-05-20 |
RU2015104537A (en) | 2016-08-27 |
MX2015000457A (en) | 2015-04-08 |
CN104427986A (en) | 2015-03-18 |
WO2014011284A1 (en) | 2014-01-16 |
CA2878251A1 (en) | 2014-01-16 |
US20150202203A1 (en) | 2015-07-23 |
KR20150036014A (en) | 2015-04-07 |
BR112015000349A2 (en) | 2017-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN10801A (en) | ||
TN2014000093A1 (en) | Method of treating gastrointestinal stromal tumors | |
IL291000A (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer | |
PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
PH12016501546A1 (en) | Cyclopropylamines as lsd1 inhibitors | |
HRP20150692T8 (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases | |
HK1210174A1 (en) | Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases | |
EP3094752A4 (en) | Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity | |
PT3418281T (en) | Compounds useful as inhibitors of atr kinase for the treatment of cancer diseases | |
HK1206743A1 (en) | 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors hif 4-- | |
MX355728B (en) | Kinase inhibitors. | |
IL232128B (en) | Tor kinase inhibitors for treatment of cancer | |
MY163852A (en) | Amidophenoxyindazoles useful as inhibitors of c-met. | |
JO3450B1 (en) | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
ZA201103476B (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
IL234602A0 (en) | Treatment of cancer with tor kinase inhibitors | |
ZA201406701B (en) | Treatment of cancer with tor kinase inhibitors | |
TN2012000469A1 (en) | Use of novel pan-cdk inhibitors for treating tumors | |
SG11201601150WA (en) | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors | |
HK1223832A1 (en) | Kinase inhibitors for the treatment of cancer | |
EP2897607A4 (en) | Inhibitors of beta-hydrolase for treatment of cancer | |
IL215199A0 (en) | Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer | |
TN2011000013A1 (en) | Amidophenoxyindazoles useful as inhibitors of c-met | |
AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer |